Ketoconazole foam - Stiefel Laboratories

Drug Profile

Ketoconazole foam - Stiefel Laboratories

Alternative Names: 2% Ketoconazole foam - Stiefel Laboratories; Extina

Latest Information Update: 31 Aug 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Stiefel Laboratories
  • Class Antifungals; Azoles; Piperazines; Small molecules
  • Mechanism of Action 14-alpha demethylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Seborrhoeic dermatitis
  • Discontinued Mycoses

Most Recent Events

  • 17 Apr 2016 Biomarkers information updated
  • 30 Aug 2011 First generic equivalent approved in the US for the topical treatment of seborrhoeic dermatitis in immunocompetent patients 12 years of age and older
  • 22 Jul 2009 Stiefel Laboratories has been acquired by GlaxoSmithKline
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top